Long-term Follow-up Study of BHC001 for TDT
ConditionThalassemia, Beta
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-35
SponsorBioray Laboratories
About this trial
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Eligibility criteria
Qualifiers
Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Assessments
Treatment groups
6 Participants
are divided into 1 treatment groupSponsors and collaborators
Bioray Laboratories
Lead sponsor
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Collaborator
Xiangya Hospital of Central South University
Collaborator
Source ClinicalTrials.gov